801 West Baltimore Street
Paragon Bioservices, Inc. is a contract research and GMP manufacturing organization (CRO, CDMO, CMO) that is focused on the development and manufacturing of biopharmaceuticals—either for research purposes or clinical trials. Working as an outsourcing partner and with a long-standing tradition of quality and service, Paragon expands the capabilities of pharmaceutical companies, biotechnology companies and federal agencies involved in the development of Monoclonal Antibodies, Therapeutic Proteins, Vaccines (VLPs) and Stem Cell-Based Therapeutics.
Industry trends and national imperatives include active consolidation in pharmaceutical companies, the advent of virtual biotechnology companies and the need for national preparedness. All of these continue to fuel the need for outsourcing—an all-encompassing practice that, today, includes the entire drug development paradigm: from the discovery bench through process development to GMP manufacturing of drug products for clinical trials. Therefore, Paragon’s corporate strategy is to provide better integration of our offerings to meet the “programmatic outsourcing needs” of our clients.
Our strategy is also to identify niche opportunities and to become the best organization to go to for R&D services and GMP manufacturing of vaccines-VLPs, monoclonal antibodies and stem cell technologies. In addition, we will continue to build infrastructure—while protecting our clients’ intellectual property through domestic R&D and manufacturing.
Founded in 1990, Paragon Bioservices is located at the University of Maryland BioPark in Baltimore. The state of Maryland is one of the best-recognized epicenters of biotechnology in the the world today—as well as home to The FDA, USDA, NIH, NIST, National Cancer Institute and a wealth of major universities. Baltimore itself is home to the world-renowned Johns Hopkins and The University of Maryland School of Medicine. Having access to these institutions—for expertise, consultation, sophisticated analytics, and a vast source of talented personnel—enhances the value of our CMO services and makes Paragon unique among its peers. Maryland is also home to hundreds of biotechnology companies that include AstraZeneca/MedImmune and Human Genome Sciences.
Paragon is focused on continuing to deliver research-grade proteins, process development services, GMP manufacturing (both microbial and mammalian platforms) and cell therapies for Phase I/II clinical trials. Our focus on biologics and efficient integration of single-use technologies allows us to keep our overhead low (as compared to other CMOs, who also provide Phase III and commercial manufacturing). We are agile, creative in problem-solving, flexible, and able to quickly engage additional shifts or added staff—in order to meet aggressive timelines.
Paragon’s business model relies on three independent revenue sources: preclinical services, GMP manufacturing and government contracting—our client base is distributed among pharmaceutical and biotechnology companies (75%) and federal agenices (25%).
Paragon is financially stable and it is presently in the midst of an expansion. Upon completion in 4Q11, the facility will have a total of 52,000 sq ft of state-of-the-art laboratories and manufacturing suites.
Key management listings
• Marco A. Chacon, PhD – President & CEO
• Robert Eberwein – Senior Vice President, GMP Operations
• Vadim Klyushinichenko – Vice President, Preclinical Services & Process Development
• Ronald A.J. Wilson - CFO
Company You Tube Video.